Laskaratos Faidon-Marios, Liu Man, Malczewska Anna, Ogunbiyi Olagunju, Watkins Jennifer, Luong Tu Vinh, Mandair Dalvinder, Caplin Martyn, Toumpanakis Christos
Centre for Gastroenterology, Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, UK.
Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Endocrine. 2020 Aug;69(2):430-440. doi: 10.1007/s12020-020-02289-2. Epub 2020 Apr 14.
Surgical resection is the only effective curative strategy for small intestinal neuroendocrine neoplasms (SINENs). Nevertheless, the evaluation of residual disease and prediction of disease recurrence/progression remains a problematic issue.
We evaluated 13 SINENs that underwent surgical resection of the primary tumour and/or mesenteric mass. Patients were divided in three groups: (a) Group 1: SINENs that underwent resection with curative intent, (b) Group 2: SINENs treated with resection in the setting of metastatic disease, which remained stable and (c) Group 3: SINENs treated with resection in the setting of metastatic disease, with evidence of any progression at follow-up. NETest and chromogranin A were measured pre-operatively and post-operatively during a 22-month median follow-up period and compared with imaging studies. NETest score <20% was determined as normal, 20-40% low, 41-79% intermediate and ≥80% high score.
NETest score was raised in all (100%) SINENs pre-operatively. Surgery with curative intent resulted in NETest score reduction from 78.25 ± 15.32 to 25.25 ± 1.75 (p < 0.05). Low NETest scores post-operatively were evident in all cases without clinical evidence of residual disease (Group 1). However, the low disease activity score suggested the presence of microscopic residual disease. In three cases (75%) with stable disease (Group 2) the NETest score was low consistent with indolent disease. In the progressive disease group (Group 3), a high NETest score was present in three cases (60%) and an intermediate NETest score in the remainder (40%).
Blood NETest scores accurately identified SINENs and were significantly decreased by curative surgery. Monitoring NETest post-operatively may facilitate management by identifying the presence of residual/progressive disease.
手术切除是小肠神经内分泌肿瘤(SINENs)唯一有效的治愈性策略。然而,对残留疾病的评估以及疾病复发/进展的预测仍然是一个有问题的问题。
我们评估了13例接受原发性肿瘤和/或肠系膜肿块手术切除的SINENs。患者分为三组:(a)第1组:以治愈为目的进行切除的SINENs;(b)第2组:在转移性疾病情况下接受切除治疗且病情保持稳定的SINENs;(c)第3组:在转移性疾病情况下接受切除治疗且随访时有任何进展证据的SINENs。在中位随访期22个月内,术前和术后测量NETest和嗜铬粒蛋白A,并与影像学研究进行比较。NETest评分<20%被确定为正常,20-40%为低分,41-79%为中等,≥80%为高分。
所有(100%)SINENs术前NETest评分均升高。以治愈为目的的手术使NETest评分从78.25±15.32降至25.25±1.75(p<0.05)。术后NETest评分低在所有无残留疾病临床证据的病例中均很明显(第1组)。然而,低疾病活动评分提示存在微小残留疾病。在3例(75%)病情稳定的病例(第2组)中,NETest评分低与惰性疾病一致。在疾病进展组(第3组)中,3例(60%)NETest评分高,其余(40%)为中等NETest评分。
血液NETest评分准确识别了SINENs,且根治性手术使其显著降低。术后监测NETest可能有助于通过识别残留/进展性疾病的存在来进行管理。